EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics

Ryan T Muir iD, Zahinoor Ismail, Sandra E Black, Eric E Smith iD

Alzheimer's & Dementia · 2024-02 · 20 (2) · 1436-1458

DOI: 10.1002/alz.13510 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 31.10.2023. Verfasst von Ryan T Muir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Cerebral Amyloid Angiopathy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes for Health Research, University of Calgary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma amyloid beta (Aβ) and tau are emerging as accessible biomarkers for Alzheimer's disease (AD). However, many assays exist with variable test performances, highlighting the need for a comparative assessment to identify the most valid assays for future use in AD and to apply to other settings in which the same biomarkers may be useful, namely, cerebral amyloid angiopathy (CAA). CAA is a progressive cerebrovascular disease characterized by deposition of Aβ 40 and Aβ 42 in cortical and leptomeningeal vessels. Novel immunotherapies for AD can induce amyloid‐related imaging abnormalities resembling CAA‐related inflammation. Few studies have evaluated plasma biomarkers in CAA. Identifying a CAA signature could facilitate diagnosis, prognosis, and a safer selection of patients with AD for emerging immunotherapies. This review evaluates studies that compare the diagnostic test performance of plasma biomarker techniques in AD and cerebrovascular and plasma biomarker profiles of CAA; it also discusses novel hypotheses and future avenues for plasma biomarker research in CAA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCerebral Amyloid AngiopathyHumansAmyloid beta-PeptidesInflammationBiomarkers

Stichwörter der Autor:innen

Alzheimer's diseaseamyloidbiomarkercerebral amyloid angiopathycerebrospinal fluiddiagnostic test performanceintracerebral hemorrhageplasmatau

Substanzen

Amyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
  • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
  • Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  • Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
  • Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • LC Campbell Cognitive Neurology Research Unit, Dr Sandra Black Centre for Brain Resilience and Recovery, and Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Ryan T Muir, Eric E Smith

Förderung

  • Canadian Institutes for Health Research
  • University of Calgary

Zitieren

APA

Muir, R. T., Ismail, Z., Black, S. E., & Smith, E. E. (2024). Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics. Alzheimer's & Dementia, 20(2), 1436-1458. https://doi.org/10.1002/alz.13510

Vancouver

Muir RT, Ismail Z, Black SE, Smith EE. Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics. Alzheimer's & Dementia. 2024;20(2):1436-1458. doi:10.1002/alz.13510

BibTeX
@article{Muir2024,
  author = {Muir, Ryan T and Ismail, Zahinoor and Black, Sandra E and Smith, Eric E},
  title = {Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {2},
  pages = {1436--1458},
  doi = {10.1002/alz.13510}
}
Kostenlos starten →